The core activity of Lallemand Pharma is the development and marketing of respiratory products classified as medicinal products or medical devices. In particular, the company focuses on the manufacture of immunostimulant drugs and medical devices based on bacterial lysates such as PMBL.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Respiratory medicines and medical devices (PMBL, Healsea)
PMBL sublingual tablets for prevention of recurrent respiratory tract infections, plus Healsea nasal sprays with Symbiofilm® for acute respiratory symptoms and chronic rhinosinusitis.
Clinical research in respiratory diseases
Clinical research to extend the documentation and therapeutic applications of PMBL, and to demonstrate efficacy and safety of the nasal spray line in acute and chronic respiratory conditions.
Scientific respiratory health information
Knowledge pages on respiratory tract immunity, respiratory biofilm, and a health manual with explanations of mucosal surfaces, immune cells, and infection defence.
Partner services and marketing materials
Partner area with launch kits, publications database, press releases, and Healsea and Ismigen materials for distribution partners.
Comparisons
Lallemand Pharma AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank Lallemand Pharma AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once Lallemand Pharma AG has claimed this profile, we'll publish editorial articles and case studies here together.